Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

R. Ceska, G. Latkovskis, MV. Ezhov, T. Freiberger, K. Lalic, O. Mitchenko, G. Paragh, Z. Petrulioniene, B. Pojskic, K. Raslova, AB. Shek, B. Vohnout, T. Altschmiedova, V. Todorovova,

. 2019 ; 21 (9) : 36. [pub] 20190622

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With "central support," more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated. RECENT FINDINGS: The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included. Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023882
003      
CZ-PrNML
005      
20201214131543.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11883-019-0797-3 $2 doi
035    __
$a (PubMed)31230174
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ceska, Richard $u Third Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. richard.ceska@vfn.cz.
245    14
$a The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project / $c R. Ceska, G. Latkovskis, MV. Ezhov, T. Freiberger, K. Lalic, O. Mitchenko, G. Paragh, Z. Petrulioniene, B. Pojskic, K. Raslova, AB. Shek, B. Vohnout, T. Altschmiedova, V. Todorovova,
520    9_
$a PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With "central support," more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated. RECENT FINDINGS: The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included. Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a anticholesteremika $x terapeutické užití $7 D000924
650    _2
$a poskytování zdravotní péče $x normy $7 D003695
650    _2
$a lidé $7 D006801
650    _2
$a hyperlipoproteinemie typ II $x diagnóza $x farmakoterapie $x epidemiologie $7 D006938
650    _2
$a incidence $7 D015994
650    12
$a mezinárodní spolupráce $7 D007391
650    _2
$a plošný screening $x metody $7 D008403
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $x imunologie $7 D000071449
650    _2
$a PCSK9 inhibitory $7 D000091362
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Latkovskis, Gustavs $u Latvian Research Institute of Cardiology, Faculty of Medicine, University of Latvia, Riga, Latvia. Paul Stradins Clinical University Hospital, Riga, Latvia.
700    1_
$a Ezhov, Marat V $u National Cardiology Research Center, Moscow, Russia.
700    1_
$a Freiberger, Tomas $u Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic. Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Lalic, Katarina $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia. Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Mitchenko, Olena $u National Registry Coordinator in Ukraine, Kiev, Ukraine.
700    1_
$a Paragh, Gyorgy $u Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Petrulioniene, Zaneta $u Vilnius University Faculty of Medicine, Vilnius, Lithuania. Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
700    1_
$a Pojskic, Belma $u Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina.
700    1_
$a Raslova, Katarina $u Coordination Center for Familial Hyperlipidemias, Slovak Medical University, Bratislava, Slovakia.
700    1_
$a Shek, Aleksandr B $u Head of Department of Ischemic Heart Disease and Atherosclerosis, Republican Specialised Center of Cardiology, Tashkent, Uzbekistan.
700    1_
$a Vohnout, Branislav $u Institute of Nutrition, Faculty of Nursing and Health Professional Studies and Coordination Centre for Familial Hyperlipoproteinemias, Slovak Medical University in Bratislava, Bratislava, Slovakia. Institute of Epidemiology, School of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Altschmiedova, Tereza $u Third Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Todorovova, Veronika $u Third Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00186151 $t Current atherosclerosis reports $x 1534-6242 $g Roč. 21, č. 9 (2019), s. 36
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31230174 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131541 $b ABA008
999    __
$a ok $b bmc $g 1596201 $s 1114558
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 21 $c 9 $d 36 $e 20190622 $i 1534-6242 $m Current atherosclerosis reports $n Curr Atheroscler Rep $x MED00186151
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...